Skip to main content
OpenTrials
Completed

NCT Number: NCT07766733

The Safety and Efficacy of Good Feeling Power® for IBD Patients

This open-label pilot study aims to evaluate the safety and efficacy of the dietary supplement Good Feeling Power® for patients with mild-to-moderate ulcerative colitis and colonic/ileal Crohn's disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ulcerative Colitis (UC) Colitis Colitis, Ulcerative Colonic Diseases Crohn Disease Crohn Disease (CD) Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centro Medico Teknon

Barcelona, 08022, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 - 64
  • BMI 18.5 - 32.0 kg/m²
  • Mild-to-moderate UC or colonic/ileal CD
  • At least one prior episode of active disease

Exclusion criteria

  • Extensive colonic resection or subtotal or total colectomy
  • Currently required or anticipated surgical intervention during the study
  • Any prior exposure to natalizumab, efalizumab, or rituximab
  • History or evidence of colonic mucosal dysplasia
  • Female patients who are lactating or have a positive pregnancy test
  • Any unstable or uncontrolled medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety.

Treatment and study plan

Good Feeling Power®

Dietary Supplement

The dietary supplement Good Feeling Power®, isolated from the fruiting bodies of the tree mushroom (tinder fungus, lat. Fomes fomentarius), was administered orally as a drink.

Primary outcomes

  1. The effect of Good Feeling Power® on gastrointestinal symptoms, biochemical biomarkers and endoscopic parameters

    Time frame: From baseline to Day180

    The primary outcomes are the changes in gastrointestinal symptoms (Simple Clinical Colitis Activity Index for ulcerative colitis (UC) patients and the Harvey-Bradshaw Index for Crohn's disease (CD) patients), biochemical biomarkers in feces (calprotectin, immunoglobulin A, hemoglobin), and endoscopic parameters (Mayo Endoscopic Score).

Secondary outcomes

  1. Safety of Good Feeling Power® for patients with mild-to-moderate UC or CD

    Time frame: From baseline to Day180

    The secondary outcomes are the safety of the tested product, as monitored by vital signs, ECG, physical condition, blood parameters (hematology, clinical chemistry, coagulation, and inflammation), urine analysis, and the absence of the product-related adverse effects.

Sponsors and collaborators

Lead sponsor

Good Feeling Products GmbH

Industry

Registry information

Official study title

An Open-Label Pilot Study to Determine Safety and Efficacy of Good Feeling Power® (a Dietary Supplement) in Patients With Either Ulcerative Colitis or Colonic/Ileal Crohn's Disease

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Aug 14, 2026
Registry last updated
Aug 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.